Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2000 Feb;44(2):453–455. doi: 10.1128/aac.44.2.453-455.2000

Characterization of TEM-56, a Novel β-Lactamase Produced by a Klebsiella pneumoniae Clinical Isolate

Catherine Neuwirth 1, Roger Labia 2,*, Eliane Siebor 1, Andre Pechinot 1, Stephanie Madec 2, El Bachir Chaibi 2, Antoine Kazmierczak 1
PMCID: PMC89705  PMID: 10639384

Abstract

TEM-56 produced by a Klebsiella pneumoniae clinical isolate is a novel β-lactamase of isoelectric point 6.4 that confers a moderate resistance level to expanded-spectrum cephalosporins. The amino acid sequence deduced from the corresponding bla gene showed two amino acid replacements with respect to the TEM-2 sequence: Glu-104 to Lys and His-153 to Arg. This enzyme showed catalytic properties close to those of TEM-18. Thus, TEM-56 appears as a new TEM mutant, an intermediary between TEM-18 and the extended-spectrum β-lactamase TEM-21.


In Dijon University Hospital, Dijon, France, Klebsiella pneumoniae isolates with decreased susceptibility to cephalosporins or aztreonam are submitted to epidemiological studies performed by analytical isoelectric focusing and pulsed-field gel electrophoresis (8, 14, 17). Over a 2-year period (1995 to 1996), 22 strains producing a β-lactamase of pI 6.4 were isolated. Analysis of chromosomal DNA by pulsed-field gel electrophoresis revealed that the 22 strains were closely related according to Tenover's criteria (24). For 21 of them, a double-disk synergy test (11) was positive between clavulanic acid and cefotaxime, whereas it was considered negative for strain Kp 395. The MICs for β-lactams of strains of the first group were similar, whereas those for the last strain differed. Kp 395 showed high MICs for penicillins and cephalothin, but the MICs were low for expanded-spectrum cephalosporins and aztreonam and similar to those seen for Escherichia coli strains producing TEM-18 (Table 1). Conversely, MICs for these agents against Kp 377 (one representative strain of the first group) were comparable to those for the TEM-3-producing strain. Clavulanic acid potentiated expanded-spectrum cephalosporins and aztreonam, but the MICs of penicillins remained high.

TABLE 1.

MICs for K. pneumoniae clinical isolates Kp 395 and Kp 377 and E. coli strains producing TEM-18, TEM-2, or TEM-3

Strain or β-lactamase produced MIC (μg/ml)a
AMX TIC PIP CFT FOX ATM CTX CAZ
K. pneumoniae
 Kp 395 (TEM-56) >8,192 (1,024) >8,192 (1,024) >2,048 (16) 512 4 (4) 1 (0.25) 0.25 (≤0.06) 4 (2)
 Kp 377 (TEM-21) >8,192 (32) >8,192 (16) 1,024 (4) 256 4 (4) 16 (0.12) 128 (≤0.06) 32 (1)
E. coli
 TEM-18 8,192 (512) 1,024 (64) 512 (16) 16 8 (8) 2 (1) 0.25 (0.12) 4 (2)
 TEM-3 8,192 (16) 8,192 (32) 256 (2) 128 4 (4) 8 (0.5) 64 (0.12) 32 (0.5)
 TEM-2 4,096 (16) 4,096 (32) 512 (2) 32 2 (2) ≤0.06 (≤0.06) ≤0.06 (≤0.06) 0.5 (0.25)
a

AMX, amoxicillin; TIC, ticarcillin; PIP, piperacillin; CFT, cephalothin; FOX, cefoxitin; ATM, aztreonam; CTX, cefotaxime; CAZ, ceftazidime. The values in parentheses are MICs in the presence of 2 μg/ml of clavulanic acid. 

For Kp 395 and Kp 377, a plasmid of 120 kb was extracted by the method of Birnboim and Doly (4), but all conjugation experiments carried to transfer resistance failed. Transformation experiments using E. coli HB 101 or E. coli DH5a competent cells failed, too. PCR analysis was performed as described previously (16) on plasmid DNA extracted from both strains with primers J (forward, 5′-CTTATTCCCTTTTTTGCGGC-3′) and E (reverse, 5′-GGTCTGACAGTTACCAATGC-3′) (6) at positions 236 and 1079 of the TEM family gene β-lactamase, respectively, with numbering according to Sutcliffe (23). The promoter region was amplified with the following primers: GOV1 (forward, 5′-ATAAAATTCTTGAAGACGAAA-3′) (16) and SIE2 (reverse, 5′-AAAACTCTCAAGGATCTTACC-3′) (this study) at positions −5 and 380, respectively. PCR products were sequenced with an Applied Biosystems 373A sequencer according to the manufacturer's instructions. Analysis of the sequences (Table 2) revealed that the two blaTEM genes were derived from blaTEM-2. Moreover, their promoter regions are identical to that of blaTEM-2.

TABLE 2.

Nucleotide substitutions in blaTEM-2, blaTEM-21, and blaTEM-56 genes

Region and nucleotide positiona Nucleotide in:
blaTEM-2 blaTEM-21 blaTEM-56
Promoter region
 32*b T T T
 175* A A A
Coding region
 226* C C C
 317* A (Lys-39c) A A
 346* G G G
 436* T T T
 512 G (Glu-104) A (Lysd) A (Lys)
 604* G G G
 660 A (His-153) G (Arg) G (Arg)
 682* C C C
 914 G (Gly-238) A (Ser) G
 925* A A A
a

Nucleotide numbering is according to that given by Sutcliffe (23) and amino acid numbering is according to Ambler et al. (1). 

b

Nucleotides marked with an asterisk are involved in the differences between blaTEM-2, blaTEM-1A, and blaTEM-1B genes (9, 10, 23). 

c

Gln for TEM-1. 

d

For TEM-21 and TEM-56, there are indicated amino acids differing from TEM-2. 

The deduced amino acid sequences of the enzymes produced by Kp 377 and Kp 395 are reported in Table 3. The enzyme produced by Kp 377 was TEM-21 of pI 6.4 (Lys-39, Lys-104, Arg-153, and Ser-238) (2, 3, 25) and that produced by Kp 395 was a new enzyme: TEM-56 of pI 6.4 also (Lys-39, Lys-104, and Arg-153). It appears that TEM-18 (Lys-39 and Lys-104) (R. Labia and D. Sirot, personal communication), TEM-56, and TEM-3 (Lys-39, Lys-104, and Ser-238) are intermediate mutants between TEM-2 and TEM-21. Within the TEM family, Arg-153 has been found only in TEM-21 and TEM-56.

TABLE 3.

Comparative kinetic parameters of β-lactamase TEM-2 and its mutants

Drug Kinetic parameters ofa:
TEM-2
TEM-18
TEM-56
TEM-3
TEM-21
kcat Km kcat/Km kcat Km kcat/Km kcat Km kcat/Km kcat Km kcat/Km kcat Km kcat/Km
Benzylpenicillin 1,500 18 83 1,400 24 58 1,400 22 63 45 6 7.5 50 9 5.5
Amoxicillin 1,200 20 60 1,300 41 31.7 1,330 40 33 31 5 6.2 43 20 2.15
Ticarcillin 195 12 16.2 280 6 47 300 7 43 9 2 4.5 7 3 2.3
Piperacillin 1,275 40 31.8 1,360 40 34 1,350 38 35 72 12 6 46 12 3.8
Cephalothin 300 350 0.86 225 135 1.7 250 140 1.8 48 23 2.1 18 55 0.33
Cephaloridine 825 800 1.0 1,360 1,200 1.1 1,350 1,200 1.1 43 30 1.4 120 120 1.0
Cefoperazone 700 230 3.0 550 170 3.2 550 180 3.0 28 20 1.4 19 30 0.63
Cefuroxime 3 1,000 <0.01 10 480 0.02 8 470 0.02 28 90 0.31 18 85 0.21
Ceftriaxone <1 ND <0.01 21 800 0.03 16 840 0.02 81 80 1 53 210 0.25
Cefotaxime 1.5 ND <0.01 35 1,660 0.02 28 1,700 0.02 202 100 2 120 400 0.3
Ceftazidime <1 ND <0.01 <1 ND <0.01 <1 ND <0.01 18 200 0.1 4 ND <0.01
a

kcat values are given in per second units, Km values are given in micromolar units, and kcat/Km values are given in per micromole per second units. The values given for kcat and Km were computed on the basis of at least three independent experiments. ND, not detected (high Km or Ki values). 

β-Lactamases TEM-2, TEM-18, TEM-56, TEM-3, and TEM-21 were purified to homogeneity according to previously described methods using ammonium sulfate precipitation, ion-exchange chromatography, and size exclusion chromatography (7, 15). Kinetic constants (Table 3) were determined by computerized microacidimetry (13), at pH 7 and 37°C, in distilled water containing 85 mM NaCl. TEM-56 hydrolyzed ceftriaxone and cefotaxime moderately, but the action on cefuroxime and ceftazidime was hardly detectable, a situation very similar to that of TEM-18. Concerning penicillins, the kinetics of TEM-56 and TEM-18 were comparable to those of TEM-2. TEM-21 and TEM-3 had considerable activity for expanded-spectrum cephalosporins and low Km values for penicillins. TEM-56, TEM-21, TEM-18, and TEM-3 enzymes are susceptible to β-lactamase inhibitors and, in some instances, more so than native TEM-2 (Table 4). Aztreonam was a poor substrate for all tested β-lactamases (data not shown).

TABLE 4.

50% inhibitory concentrations (IC50s) of β-lactamase inhibitors for β-lactamase TEM-2 and its mutants

β-Lactamase IC50 (μM) of:
Clavulanic acid Sulbactam Tazobactam
TEM-2 0.16 8 0.1
TEM-18 0.007 4.2 0.1
TEM-56 0.008 4.3 0.1
TEM-3 0.01 0.4 0.01
TEM-21 0.01 2 0.07

TEM-18 and TEM-56 gave similar and moderate decreases in susceptibility levels of cefotaxime, ceftazidime, and aztreonam. On the contrary, TEM-21 and TEM-3 conferred a high level of resistance to expanded-spectrum cephalosporins. This indicates that the Glu-104 to Lys amino acid substitution enables the mutant to hydrolyze these cephalosporins but not enough to confer a true resistance, as already noticed in the variants obtained by site-directed mutagenesis (18, 20, 22, 27). Conversely, the substitution of Gly-238 for Ser has a key role, as already demonstrated (5, 21, 26). Concerning the His-153 for Arg amino acid substitution, comparison of TEM-56 and TEM-18, on one hand, and TEM-21 and TEM-3, on the other hand, shows that this substitution does not significantly modify the hydrolytic properties of the enzyme, as also shown by enzyme kinetics.

Comparison of a large set of class A β-lactamase sequences (12, 19) shows that residue 153 is not conserved, but the most frequently encountered is arginine. The role of the His-153 for Arg amino acid substitution remains unclear. Often, extended-spectrum or inhibitor-resistant TEM-derived β-lactamases may present one or a few secondary amino acid substitutions whose roles are not always elucidated. Within presently reported TEM mutant β-lactamases, about 10 positions have been described (http://www.lahey.org/studies/webt.htm).

It is noteworthy that the first of the 22 strains producing an enzyme of pI 6.4 was Kp 395, producing TEM-56. This strain was isolated from a patient who had received multiple β-lactam therapies, and TEM-56 was detected only once. Then Kp 377, producing TEM-21, was isolated from a patient in the same ward. This suggests that blaTEM-21, which differs from blaTEM-56 by a single base at position 914, was selected under antibiotic pressure in vivo. Then the strain spread in the ward and in other departments subsequent to patients' transfers.

Acknowledgments

C.N. and R.L. contributed equally to this work.

REFERENCES

  • 1.Ambler R P, Coulson A F W, Frère J M, Ghuysen J M, Joris B, Forsman M, Levesque R C, Tirabi G, Waley S G. A standard numbering scheme for the class A β-lactamases. Biochem J. 1991;276:269–272. doi: 10.1042/bj2760269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Arlet G, Brami G, Decré D, Filippo A, Gaillot O, Lagrange P H, Philippon A. Molecular characterisation by PCR-restriction fragment length polymorphism of TEM β-lactamases. FEMS Microbiol Lett. 1995;134:203–208. doi: 10.1111/j.1574-6968.1995.tb07938.x. [DOI] [PubMed] [Google Scholar]
  • 3.Arlet G, Goussard S, Courvalin P, Philippon A. Sequences of the genes for the TEM-20, TEM-21, TEM-22, and TEM-29 extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1999;43:969–971. doi: 10.1128/aac.43.4.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Birnboim H C, Doly J. Rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 1979;7:1513–1523. doi: 10.1093/nar/7.6.1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cantu C, III, Huang W, Palzkill T. Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 β-lactamase with altered substrate specificity for aztreonam and ceftazidime. J Biol Chem. 1996;271:22538–22545. doi: 10.1074/jbc.271.37.22538. [DOI] [PubMed] [Google Scholar]
  • 6.Chanal C, Poupart M C, Sirot D, Labia R, Sirot J, Cluzel R. Nucleotide sequences of CAZ-2, CAZ-6, and CAZ-7 β-lactamase genes. Antimicrob Agents Chemother. 1992;36:1817–1820. doi: 10.1128/aac.36.9.1817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Farzaneh S, Chaibi E B, Péduzzi J, Barthélémy M, Labia R, Blazquez J, Baquero F. Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) β-lactamase. Antimicrob Agents Chemother. 1996;40:2434–2436. doi: 10.1128/aac.40.10.2434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gouby A, Neuwirth C, Bourg G, Bouzigues N, Carles-Nurit M J, Despaux E, Ramuz M. Epidemiological study by pulsed-field gel electrophoresis of an outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a geriatric hospital. J Clin Microbiol. 1994;32:301–305. doi: 10.1128/jcm.32.2.301-305.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Goussard S, Courvalin P. Sequence of the genes blaT-1B and blaT-2. Gene. 1991;102:71–73. doi: 10.1016/0378-1119(91)90540-r. [DOI] [PubMed] [Google Scholar]
  • 10.Heffron F, McCarty B J, Ohtsubo H, Ohtsubo E. DNA sequence analysis of the transposon tn3: three genes and three sites involved in transposition of tn3. Cell. 1979;18:1153–1163. doi: 10.1016/0092-8674(79)90228-9. [DOI] [PubMed] [Google Scholar]
  • 11.Jarlier V, Nicolas M H, Fournier G, Philippon A. Extended broad-spectrum β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988;10:867–878. doi: 10.1093/clinids/10.4.867. [DOI] [PubMed] [Google Scholar]
  • 12.Joris B, Ledent P, Dideberg O, Fonzé E, Lamotte-Brasseur J, Kelly J A, Ghuysen J M, Frère J M. Comparison of the sequences of class A β-lactamases and of the secondary structure elements of penicillin-recognizing proteins. Antimicrob Agents Chemother. 1991;35:2294–2301. doi: 10.1128/aac.35.11.2294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Labia R, Andrillon J, Le Goffic F. Computerized microacidimetric determination of beta-lactamase Michaelis-Menten constants. FEBS Lett. 1973;33:42–44. doi: 10.1016/0014-5793(73)80154-1. [DOI] [PubMed] [Google Scholar]
  • 14.Labia R, Barthélémy M, Masson J M. Multiplicité des β-lactamases: un problème d'isoenzymes? C R Acad Sci (Paris) 1976;283D:1597–1600. [PubMed] [Google Scholar]
  • 15.Lenfant F, Labia R, Masson J M. Replacement of lysine 234 affects transition state stabilization in the active site of β-lactamase TEM1. J Biol Chem. 1991;266:17187–17194. [PubMed] [Google Scholar]
  • 16.Mabilat C, Goussard S. PCR detection and identification of genes for extended-spectrum β-lactamases. In: Persing D H, Smith T F, Tenover F C, White T J, editors. Diagnostic molecular microbiology: principles and applications. Washington, D.C.: American Society for Microbiology; 1993. pp. 553–563. [Google Scholar]
  • 17.Neuwirth C, Siébor E, Lopez J, Péchinot A, Kazmierczak A. Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum β-lactamase to other members of the family Enterobacteriaceae. J Clin Microbiol. 1996;34:76–79. doi: 10.1128/jcm.34.1.76-79.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Palzkill T, Botstein D. Identification of amino acid substitutions that alter the substrate specificity of TEM-1 β-lactamase. J Bacteriol. 1992;174:5237–5243. doi: 10.1128/jb.174.16.5237-5243.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Péduzzi J, Reynaud A, Baron P, Barthélémy M, Labia R. Chromosomally encoded cephalosporinase of Proteus vulgaris Ro104 belongs to Ambler's class A. Biochim Biophys Acta. 1994;1207:31–39. doi: 10.1016/0167-4838(94)90048-5. [DOI] [PubMed] [Google Scholar]
  • 20.Petit A, Maveyraud L, Lenfant F, Samama J P, Labia R, Masson J M. Multiple substitutions at position 104 of β-lactamase TEM-1: assessing the role of this residue in substrate specificity. Biochem J. 1995;305:33–40. doi: 10.1042/bj3050033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Saves I, Burlet-Schilt I, Maveyraud L, Samama J P, Promé J C, Masson J M. Mass spectral kinetic study of acylation and deacylation during the hydrolysis of penicillins and cefotaxime by β-lactamase TEM-1 and the G238S mutant. Biochemistry. 1995;34:11660–11667. doi: 10.1021/bi00037a003. [DOI] [PubMed] [Google Scholar]
  • 22.Sowek J A, Singer S B, Ohringer S, Malley M F, Dougherty T J, Gougoutas J Z, Bush K. Substitution of lysine at position 104 or 240 of TEM-1 pTS18R β-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry. 1991;30:3179–3188. doi: 10.1021/bi00227a004. [DOI] [PubMed] [Google Scholar]
  • 23.Sutcliffe J G. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci USA. 1978;8:3737–3741. doi: 10.1073/pnas.75.8.3737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Tenover F C, Arbeit R D, Goering R V, Mickelsen P A, Murray B E, Persing D H, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–2239. doi: 10.1128/jcm.33.9.2233-2239.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tessier F, Arpin C, Allery A, Quentin C. Molecular characterization of a TEM-21 β-lactamase in a clinical isolate of Morganella morganii. Antimicrob Agents Chemother. 1998;42:2125–2127. doi: 10.1128/aac.42.8.2125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Venkatachalam K V, Huang W, La Rocco M, Palzkill T. Characterization of TEM-1 β-lactamase mutants from position 238 to 241 with increased catalytic efficiency for ceftazidime. J Biol Chem. 1994;269:23444–23450. [PubMed] [Google Scholar]
  • 27.Viadiu H, Osuna J, Fink A L, Soberon X. A new TEM β-lactamase double mutant with broadened specificity reveals substrate-dependent functional interactions. J Biol Chem. 1995;270:781–787. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES